buspirone has been researched along with Cognitive Dysfunction in 2 studies
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.
Cognitive Dysfunction: Diminished or impaired mental and/or intellectual function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a 24-week, randomized, double-blind parallel-controlled trial to test whether buspirone is beneficial to improve cognitive deficits of schizophrenia because it remains unclear." | 9.30 | Co-treatment of buspirone with atypical antipsychotic drugs (AAPDs) improved neurocognitive function in chronic schizophrenia. ( Deng, W; Guo, W; Li, T; Ma, X; Song, X; Tian, H; Wang, J; Wang, Q; Wang, Y; Wei, J; Wei, M; Yang, X; Zhao, L; Zheng, C, 2019) |
| "We conducted a 24-week, randomized, double-blind parallel-controlled trial to test whether buspirone is beneficial to improve cognitive deficits of schizophrenia because it remains unclear." | 5.30 | Co-treatment of buspirone with atypical antipsychotic drugs (AAPDs) improved neurocognitive function in chronic schizophrenia. ( Deng, W; Guo, W; Li, T; Ma, X; Song, X; Tian, H; Wang, J; Wang, Q; Wang, Y; Wei, J; Wei, M; Yang, X; Zhao, L; Zheng, C, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hogendorf, AS | 1 |
| Hogendorf, A | 1 |
| Kurczab, R | 1 |
| Kalinowska-Tłuścik, J | 1 |
| Popik, P | 1 |
| Nikiforuk, A | 1 |
| Krawczyk, M | 1 |
| Satała, G | 1 |
| Lenda, T | 1 |
| Knutelska, J | 1 |
| Bugno, R | 1 |
| Staroń, J | 1 |
| Pietruś, W | 1 |
| Matłoka, M | 1 |
| Dubiel, K | 1 |
| Moszczyński-Pętkowski, R | 1 |
| Pieczykolan, J | 1 |
| Wieczorek, M | 1 |
| Pilarski, B | 1 |
| Zajdel, P | 1 |
| Bojarski, AJ | 1 |
| Wang, Y | 1 |
| Yang, X | 1 |
| Song, X | 1 |
| Zhao, L | 1 |
| Wei, J | 1 |
| Wang, J | 1 |
| Tian, H | 1 |
| Zheng, C | 1 |
| Wei, M | 1 |
| Wang, Q | 1 |
| Guo, W | 1 |
| Deng, W | 1 |
| Li, T | 1 |
| Ma, X | 1 |
1 trial available for buspirone and Cognitive Dysfunction
| Article | Year |
|---|---|
Co-treatment of buspirone with atypical antipsychotic drugs (AAPDs) improved neurocognitive function in chronic schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Anxiety; Buspirone; Cognition; Cognitive Dysfunction; Depre | 2019 |
1 other study available for buspirone and Cognitive Dysfunction
| Article | Year |
|---|---|
2-Aminoimidazole-based antagonists of the 5-HT
Topics: Animals; Cells, Cultured; Cognitive Dysfunction; Dose-Response Relationship, Drug; Drug Design; HEK2 | 2019 |